Emergent BioSolutions has secured exclusive commercial rights to Kloxxado, an 8-mg naloxone nasal spray, from Hikma Pharmaceuticals for the U.S. and Canada. This move is part of Emergent's strategy to stabilize and transform the company under CEO Joseph Papa. Kloxxado, an 8 mg version of naloxone, will be distributed alongside 4 mg doses of Narcan to enhance the company's offerings in combating opioid overdoses.